Jonathan Leeman

A novel master clinical trial applied to stereotactic MRI guided adaptive radiotherapy (SMART) demonstrates low rates of toxicity and highlights the benefits of the master protocol approach: oxford.ly/3XuGEGr @jonathan_leeman

🔔Education Opportunity for Patients with #ProstateCancer & Their Families 📆 5/17/24 8amEST (virtual) Here from experts discussing ✴️ Diet/Lifestyle 🚴‍♂️ ✴️ AI 🤖 ✴️ Biochemical Recurrence 📈 ✴️ Genetics 🧬 ✴️ Survivorship ☺️ Register for FREE! ✍🏽 Link: shorturl.at/ehjx8

🔬 Congrats to @LeeGraceMD & our MR-guided #RT team @BrighamWomens /@DanaFarber for our study on 5-fx stereotactic #MRI-guided adaptive #Radiotherapy for high-risk thoracic oligo-mets (19 ultra+7 central), now out in @RadiotherapyOn1. #Cancer #LCSM #radonc #f0015" target="_blank" rel="nofollow noopener">sciencedirect.com/science/articl…

Without a quick and comprehensive resolution, the #MRIdian platform will disappear. Patients will miss out, and technical innovation in radiotherapy will be derailed. But we will not go quietly into that good night… read our open letter to the #radonc community👍

Our top 5 articles from the week, with: @AlexSpiraMDPhD @JSabari @DasMillie11 @MNagasaka @tarasanftmd @jonathan_leeman 1. bit.ly/3PiEGV3 2. bit.ly/3PlPZvL 3. bit.ly/3sVwMJN 4. bit.ly/3LrQQdk 5. bit.ly/3LlCvif

Exciting news! We're hiring for a new Director of GU Radiation Oncology @MSKCancerCenter. Big shoes to fill,but an awesome opportunity to run a large service with a lot of active research, trials,and technology. #radonc @MSK_RadOnc @ASTRO_org #medtwitter externaltalent-mskcc.icims.com/jobs/72288/cli…

1/ Check out this preprint that describes how we developed and validated a new #AI-based biomarker that we are calling “FaceAge”, which uses a simple face #photo to predict outcomes in #cancer patients! medrxiv.org/content/10.110… #oncology #AImedicine #FaceAge

🌟 @HElhalawaniMD and Dr Veena Venkatachalam treated 11 yr old Celeste with novel MR-LINAC bwhbulletin.org/2023/08/24/rad…

In a new @JAMANetworkOpen study, @BenjaminKannMD & @DanaFarber researchers developed an AI model to diagnose muscle wasting, known as sarcopenia, using CT scans in patients with head and neck cancer, aiding timely interventions. Release here ➡️ ms.spr.ly/60149JXU8

Join us Sept. 22 for the X-Ray-Guided Online Adaptive Radiotherapy Symposium in Dallas! This symposium will provide a full day of presentations and interactive sessions with leading experts in adaptive radiotherapy. For more info and registration: bit.ly/3OpfZHp

New in #ProstateCancer research | This meta-analysis of prostate SBRT studies found a significant reduction in the risk of acute urinary and GI side effects with MR-guided daily adaptive SBRT compared to standard CT-guided SBRT. 🔗acsjournals.onlinelibrary.wiley.com/doi/full/10.10… @jonathan_leeman @BrighamRadOnc @OncoAlert @WalterStadler5 @WileyOnc_Hem #PCSM

Happy to share our latest study. We validated our deep learning ENE algorithm in the context of the @eaonc E3311 HPV+OPC de-escalation trial. Congratulations and a huge thank you all the co-authors for their help on this large, multi-institutional effort. 1/x

📢 CALL FOR PAPERS - We are inviting submissions to a collection on #cancer therapy #toxicity, guest edited by Drs. Raymond Mak (@Dr_RayMak), Miranda Fidler-Benaoudia (@MirandaFidlerB) & Lova Sun. Find out more: ow.ly/GGAK50Ngy5p

@sophia_kamran @MSKCancerCenter Thank you! Can’t wait to join forces again with the great @sophia_kamran ! @BrighamRadOnc @MGHCancerCenter

From @MSKCancerCenter transitional year to Boston to ⬇️, excited for this collaborative effort 🤝across both sides of town! 🙏🏽grateful for the opportunity. The @MSKCancerCenter TY bond is real…💪🏽 #teamscience #radonc ☢️☢️

📢Pleased to announce the recipients of the inaugural ☢️Radiation Oncology Accelerator Awards 🥇🥇 intended to foster collaborations between @DanaFarber/@BrighamWomens & @MGHCancerCenter #radonc Incredibly deserving group of early-stage investigators 🔥👏 #teamscience

🆕Does PSA at time of salvage therapy after radical prostatectomy for prostate cancer matter? Tilki, D'Amico, and co-authors report multinational findings here: pubmed.ncbi.nlm.nih.gov/36857638/

@rweichselbaum @EvanThomas84 @radiopeppe @HenningWillers @BenjaminKannMD @SBRT_CR Here is the latest: do we need to consider histologic subtype for NSCLC in #radonc ? An editorial with @maraantonoff and Dr. Annikka Weissferdt of @MDAndersonNews authors.elsevier.com/a/1gdao1Hx52CO… HT @jonathan_leeman #lcsm #tssmn cc @ElliotServaisMD @BrendonStilesMD @JFreemanDaily

Abs#298 @ASCO #GU23 👉bit.ly/3E4TrX0: In pts with localized #prostatecancer (T1-T2; Gleason ≤ 3 + 4; PSA ≤ 20 ng/mL) ➡️ radiation (SBRT) associated with better urinary continence & sexual bother but more bowel bother after 2 yrs vs surgery @urotoday @PCFnews @Uromigos

@AmarUKishan @HimanshuNagarMD @JZ_GER I wonder about EUS and bladder trigone which likely get more dose with 4mm PTV and MR fusion vs 2mm PTV with no fusion. Could be a really interesting secondary analysis. Congrats Amar!

@HimanshuNagarMD @JZ_GER Major area of interest moving forward is to define the important OARs for urinary toxicity. Obviously not just the prostatic urethra that matters.

Pleased to share the primary endpoint results of the randomized phase III MIRAGE trial evaluating whether aggressive margin reduction with MRI-guidance leads to reduced toxicity in the context of prostate SBRT, out today in @JAMAOncology jamanetwork.com/journals/jamao… (1/n)

I asked ChatGPT to give me 22 common regrets people have on their deathbeds The results were eye-openers: